"Sole book running manager" is why they do this deal. And, they obviously have faith in the LT outlook of EXAS.
I was an EXAS uber bull from 2015 - 2019, but sold completely out of my position last year after the run-up. Cologuard growth appears to be slowing/fading much more quickly than originally forecasted. EXAS is burning thru $400M/year in sales and marketing, but the CG growth just isn't keeping up and the pipeline has been slow to develop. They needed this raise after the Genomic Health acquisition.
Now....to bring it back to AMRN. EXAS was a Wall St. darling from 2017 - 2019, growing revs 80% per year and enjoying rich valuations of ~ 16 CY revs. Can anyone else think of a company that's sitting on the launch pad, growing revs 70% - 90% per year and have only penetrated a tiny portion of their addressable market? We also don't have any competition (unlike colonoscopy for CG) and have WAY less (none) insurance/CMS reimbursement issues to be concerned with and Vascepa will be an international blockbuster (again, unlike CG).
PS - we currently sit at 8x CY revs.....
2020 is the year of AMRN!
Market Data 
Markets 
AI
